Jazz Pharmaceuticals
JAZZ
280 hedge funds and large institutions have $6.17B invested in Jazz Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 74 increasing their positions, 126 reducing their positions, and 28 closing their positions.
121% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 28
33% more call options, than puts
Call options by funds: $66.1M | Put options by funds: $49.5M
33% more funds holding in top 10
Funds holding in top 10: 12 → 16 (+4)
31% more capital invested
Capital invested by funds: $4.72B → $6.17B (+$1.44B)
12% more funds holding
Funds holding: 249 → 280 (+31)
41% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 126
Top Buyers
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$242M |
| 2 |
HCM
Hoplite Capital Management
New York
|
+$112M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.2M |
| 4 |
Two Sigma Investments
New York
|
+$35.4M |
| 5 |
Two Sigma Advisers
New York
|
+$28.3M |
Top Sellers
| 1 |
WBC
Westpac Banking Corp
Sydney,
Australia
|
-$274M |
| 2 |
PC
Paulson & Co
New York
|
-$88.6M |
| 3 |
Calamos Advisors
Naperville,
Illinois
|
-$65.3M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$57.7M |
| 5 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
-$56.7M |
JAZZ Hedge Fund Activity: Q4 2013 in Review
280 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2013, worth a combined $6.17B — up 31% from $4.72B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new JAZZ positions and 28 closed out — a net gain of 34 holders — while 74 added to existing stakes and 126 trimmed.
The largest buyer was Putnam Investments, adding an estimated $242M. The largest seller was Westpac Banking Corp, cutting an estimated $274M.
- 280 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2013, up from 249 in Q3 2013.
- Funds reported $6.17B of Jazz Pharmaceuticals stock for Q4 2013, up 31% quarter-over-quarter.
- 62 funds opened new Jazz Pharmaceuticals positions in Q4 2013 and 28 closed out, a net change of +34 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2013 was Putnam Investments, an estimated $242M added.
- The largest Jazz Pharmaceuticals seller in Q4 2013 was Westpac Banking Corp, an estimated $274M sold.
Based on aggregated 13F filings for Q4 2013.